Journal of Oncology Pharmacy Practice, volume 22, issue 2, pages 205-211
Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective
Dranitsaris George
1
,
Yu Bo
2
,
Wang Leiping
2
,
Sun Weili
3
,
Zhou Yan
4
,
King Jennifer
5
,
Kaura Satyin
5
,
Zhang Adams
5
,
1
Augmentium Pharma Consulting, Toronto, Canada
|
2
Cancer Hospital of Fu Dan University, Shanghai, China
|
3
Jiangsu Provincial Cancer Hospital, Jiangsu, China
|
4
Shanghai Centennial Scientific, Shanghai, China
|
5
Celgene Corporation, Summit, NJ, USA
|
Publication type: Journal Article
Publication date: 2014-10-14
Quartile SCImago
Q3
Quartile WOS
Q4
Impact factor: 1.3
ISSN: 10781552, 1477092X
Oncology
Pharmacology (medical)
Abstract
Background
Abraxane® and Taxol® are both effective drugs for the treatment of advanced stage breast cancer. However, each agent possesses unique drug delivery characteristics with the former not requiring premedication and having a considerably shorter recommended infusion time (i.e. 30 min vs. 2–4 h). To measure the overall efficiency and cost-saving potential associated with Abraxane® relative to Taxol®, a time and motion study was undertaken in breast cancer patients treated in China.
Methods
Baseline patient data collection included age, disease stage, number and sites of metastatic disease, and performance status. Time and resource use data were then collected from breast patients being treated with Abraxane® ( n = 12) or Taxol® ( n = 15) in one of three cancer clinics located in Jiangsu, Shanghai, and Beijing. Resource use and time impact on clinical staff were quantified using unit cost estimates. This included costs for drug preparation, administration, materials and supplies, premedication, patient chair time, labor costs, and all acute adverse drug reactions. Outcomes were presented as a mean total time and cost for delivering a dose of Abraxane® or Taxol® and were compared using parametric and non-parametric statistical tests where appropriate. All costs were reported in US dollars (US$1 = 6.1 RMB, as of January 2014).
Results
Patients were comparable with respect to mean age, number of metastatic sites, and performance status. Approximately 9 of 12 (75%) patients received Abraxane® as on a weekly schedule (vs. every 3 weeks) compared to 6 of 15 (40%) with Taxol®. There were 5 (33.3%) acute adverse drug reactions with Taxol®, 3 of which required a physician visit and the initiation of supportive interventions. In contrast, there was only one minor event with Abraxane® (8.3%), which was easily managed with a temporary stoppage of the infusion. From the time and motion study, the mean total time for Abraxane® and Taxol® delivery (preparation, administration, premedication, total chair time, and adverse effects management) was 84 and 282 min respectively ( p < 0.001), with the associated costs being US$59 and US$254 respectively per dose ( p < 0.001).
Conclusion
To our knowledge, this is first such study in breast cancer patients to be undertaken in China. Abraxane® was associated with fewer acute adverse drug reactions and significant reductions in health care resources, physician/nurse time and overall drug delivery costs compared to Taxol®.
Citations by journals
|
1
2
|
|
|
Nanomedicine
|
Nanomedicine
2 publications, 5.56%
|
|
Journal of Nanobiotechnology
|
Journal of Nanobiotechnology
2 publications, 5.56%
|
|
Drug development & registration
|
Drug development & registration
1 publication, 2.78%
|
|
Medicine (United States)
|
Medicine (United States)
1 publication, 2.78%
|
|
Nanomaterials
|
Nanomaterials
1 publication, 2.78%
|
|
Molecules
|
Molecules
1 publication, 2.78%
|
|
Cancer Chemotherapy and Pharmacology
|
Cancer Chemotherapy and Pharmacology
1 publication, 2.78%
|
|
Scientific Reports
|
Scientific Reports
1 publication, 2.78%
|
|
Advanced Fiber Materials
|
Advanced Fiber Materials
1 publication, 2.78%
|
|
Chemical Engineering Journal
|
Chemical Engineering Journal
1 publication, 2.78%
|
|
Talanta
|
Talanta
1 publication, 2.78%
|
|
European Journal of Pharmaceutical Sciences
|
European Journal of Pharmaceutical Sciences
1 publication, 2.78%
|
|
Advanced Drug Delivery Reviews
|
Advanced Drug Delivery Reviews
1 publication, 2.78%
|
|
Biomaterials
|
Biomaterials
1 publication, 2.78%
|
|
Advanced healthcare materials
|
Advanced healthcare materials
1 publication, 2.78%
|
|
ACS Applied Bio Materials
|
ACS Applied Bio Materials
1 publication, 2.78%
|
|
Nanomedicine: Nanotechnology, Biology, and Medicine
|
Nanomedicine: Nanotechnology, Biology, and Medicine
1 publication, 2.78%
|
|
Clinical Pharmacology and Therapeutics
|
Clinical Pharmacology and Therapeutics
1 publication, 2.78%
|
|
Oncologist
|
Oncologist
1 publication, 2.78%
|
|
Nanotechnology Reviews
|
Nanotechnology Reviews
1 publication, 2.78%
|
|
Journal of Nanomaterials
|
Journal of Nanomaterials
1 publication, 2.78%
|
|
Small
|
Small
1 publication, 2.78%
|
|
ACS applied materials & interfaces
|
ACS applied materials & interfaces
1 publication, 2.78%
|
|
Molecular Pharmaceutics
|
Molecular Pharmaceutics
1 publication, 2.78%
|
|
Planta Medica
|
Planta Medica
1 publication, 2.78%
|
|
European Journal of Pharmaceutics and Biopharmaceutics
|
European Journal of Pharmaceutics and Biopharmaceutics
1 publication, 2.78%
|
|
Risk Management and Healthcare Policy
|
Risk Management and Healthcare Policy
1 publication, 2.78%
|
|
European Physical Journal E
|
European Physical Journal E
1 publication, 2.78%
|
|
1
2
|
Citations by publishers
|
1
2
3
4
5
6
7
|
|
|
Elsevier
|
Elsevier
7 publications, 19.44%
|
|
Springer Nature
|
Springer Nature
6 publications, 16.67%
|
|
Wiley
|
Wiley
3 publications, 8.33%
|
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
3 publications, 8.33%
|
|
Future Medicine
|
Future Medicine
2 publications, 5.56%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 5.56%
|
|
Center of Pharmaceutical Analytics Ltd
|
Center of Pharmaceutical Analytics Ltd
1 publication, 2.78%
|
|
Wolters Kluwer Health
|
Wolters Kluwer Health
1 publication, 2.78%
|
|
Society for Translational Oncology
|
Society for Translational Oncology
1 publication, 2.78%
|
|
Walter de Gruyter
|
Walter de Gruyter
1 publication, 2.78%
|
|
Hindawi Limited
|
Hindawi Limited
1 publication, 2.78%
|
|
Thieme
|
Thieme
1 publication, 2.78%
|
|
Dove Medical Press
|
Dove Medical Press
1 publication, 2.78%
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2016,2017,2018,2019,2020,2021,2022,2023],"ids":[0,0,0,0,0,0,0,0],"codes":[0,0,0,0,0,0,0,0],"imageUrls":["","","","","","","",""],"datasets":[{"label":"Citations number","data":[2,8,0,3,3,7,4,9],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["5.56","22.22",0,"8.33","8.33","19.44","11.11","25"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Nanomedicine","Journal of Nanobiotechnology","Drug development & registration","Medicine (United States)","Nanomaterials","Molecules","Cancer Chemotherapy and Pharmacology","Scientific Reports","Advanced Fiber Materials","Chemical Engineering Journal","Talanta","European Journal of Pharmaceutical Sciences","Advanced Drug Delivery Reviews","Biomaterials","Advanced healthcare materials","ACS Applied Bio Materials","Nanomedicine: Nanotechnology, Biology, and Medicine","Clinical Pharmacology and Therapeutics","Oncologist","Nanotechnology Reviews","Journal of Nanomaterials","Small","ACS applied materials & interfaces","Molecular Pharmaceutics","Planta Medica","European Journal of Pharmaceutics and Biopharmaceutics","Risk Management and Healthcare Policy","European Physical Journal E"],"ids":[22187,11794,26766,19945,10051,1770,17457,13767,27328,16275,4331,9338,12266,13732,21975,21728,8468,7703,7432,15551,20485,9872,1458,19735,9840,25165,2595,10807],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/ewwj5yBvA6wToa4jkXRrcDjN2omUCp6UYltwKhS8_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/sfY8MSm2JdWlg1g91zFkR9FIaCyrBVDo7ouIv6jL_medium.webp","\/storage\/images\/resized\/3SpVxcYL33bOvPq4sHxJLH2NeKNeDloahSUpNiO4_medium.webp","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/xqixcltwJYe6H8Uco2JbAFfIOzt7UNKH0OcPOPzO_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp"],"datasets":[{"label":"","data":[2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[5.56,5.56,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78,2.78],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","Springer Nature","Wiley","American Chemical Society (ACS)","Future Medicine","Multidisciplinary Digital Publishing Institute (MDPI)","Center of Pharmaceutical Analytics Ltd","Wolters Kluwer Health","Society for Translational Oncology","Walter de Gruyter","Hindawi Limited","Thieme","Dove Medical Press"],"ids":[17,8,11,40,6949,202,7156,32,2484,4,6921,135,417],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/ewwj5yBvA6wToa4jkXRrcDjN2omUCp6UYltwKhS8_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/sfY8MSm2JdWlg1g91zFkR9FIaCyrBVDo7ouIv6jL_medium.webp","\/storage\/images\/resized\/3SpVxcYL33bOvPq4sHxJLH2NeKNeDloahSUpNiO4_medium.webp","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/xqixcltwJYe6H8Uco2JbAFfIOzt7UNKH0OcPOPzO_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp"],"datasets":[{"label":"","data":[7,6,3,3,2,2,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[19.44,16.67,8.33,8.33,5.56,5.56,2.78,2.78,2.78,2.78,2.78,2.78,2.78],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Dranitsaris G. et al. Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective // Journal of Oncology Pharmacy Practice. 2014. Vol. 22. No. 2. pp. 205-211.
GOST all authors (up to 50)
Copy
Dranitsaris G., Yu B., Wang L., Sun W., Zhou Y., King J., Kaura S., Zhang A., Yuan P. Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective // Journal of Oncology Pharmacy Practice. 2014. Vol. 22. No. 2. pp. 205-211.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1177/1078155214556008
UR - https://doi.org/10.1177%2F1078155214556008
TI - Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective
T2 - Journal of Oncology Pharmacy Practice
AU - Yu, Bo
AU - Wang, Leiping
AU - Sun, Weili
AU - King, Jennifer
AU - Kaura, Satyin
AU - Zhang, Adams
AU - Yuan, Peng
AU - Dranitsaris, George
AU - Zhou, Yan
PY - 2014
DA - 2014/10/14 00:00:00
PB - SAGE
SP - 205-211
IS - 2
VL - 22
SN - 1078-1552
SN - 1477-092X
ER -
Cite this
BibTex
Copy
@article{2014_Dranitsaris,
author = {Bo Yu and Leiping Wang and Weili Sun and Jennifer King and Satyin Kaura and Adams Zhang and Peng Yuan and George Dranitsaris and Yan Zhou},
title = {Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective},
journal = {Journal of Oncology Pharmacy Practice},
year = {2014},
volume = {22},
publisher = {SAGE},
month = {oct},
url = {https://doi.org/10.1177%2F1078155214556008},
number = {2},
pages = {205--211},
doi = {10.1177/1078155214556008}
}
Cite this
MLA
Copy
Dranitsaris, George, et al. “Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.” Journal of Oncology Pharmacy Practice, vol. 22, no. 2, Oct. 2014, pp. 205-211. https://doi.org/10.1177%2F1078155214556008.